TRCT
ANIK icon

Tower Research Capital (TRC)’s Anika Therapeutics ANIK Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Sell
880
-717
-45% -$8.32K ﹤0.01% 3774
2025
Q4 		$15.3K Sell
1,597
-189
-11% -$1.81K ﹤0.01% 3290
2025
Q3 		$16.8K Sell
1,786
-163
-8% -$1.56K ﹤0.01% 3460
2025
Q2 		$20.6K Buy
1,949
+1,175
+152% +$14.8K ﹤0.01% 3664
2025
Q1 		$11.6K Sell
774
-2,116
-73% -$35.2K ﹤0.01% 3522
2024
Q4 		$47.6K Buy
2,890
+2,326
+412% +$45.9K ﹤0.01% 2587
2024
Q3 		$13.9K Sell
564
-7,811
-93% -$203K ﹤0.01% 3486
2024
Q2 		$212K Buy
8,375
+8,231
+5,716% +$213K ﹤0.01% 2024
2024
Q1 		$3.66K Sell
144
-2,960
-95% -$71.6K ﹤0.01% 4824
2023
Q4 		$70.3K Buy
3,104
+1,947
+168% +$40.3K ﹤0.01% 2909
2023
Q3 		$21.6K Sell
1,157
-2,089
-64% -$43.3K ﹤0.01% 3302
2023
Q2 		$84.3K Buy
3,246
+2,526
+351% +$67.6K ﹤0.01% 2157
2023
Q1 		$21K Sell
720
-3,575
-83% -$106K ﹤0.01% 3368
2022
Q4 		$128K Buy
4,295
+2,694
+168% +$76.6K 0.01% 1631
2022
Q3 		$38K Buy
1,601
+608
+61% +$14K ﹤0.01% 3395
2022
Q2 		$22K Sell
993
-1,063
-52% -$23.7K ﹤0.01% 3682
2022
Q1 		$51K Buy
2,056
+549
+36% +$16.7K ﹤0.01% 2699
2021
Q4 		$54K Buy
1,507
+320
+27% +$12.8K ﹤0.01% 2703
2021
Q3 		$50K Buy
1,187
+446
+60% +$18.4K ﹤0.01% 2955
2021
Q2 		$32K Buy
741
+211
+40% +$8.99K ﹤0.01% 3411
2021
Q1 		$21K Buy
530
+124
+31% +$4.7K ﹤0.01% 3829
2020
Q4 		$18K Sell
406
-110
-21% -$4.17K ﹤0.01% 3923
2020
Q3 		$18K Sell
516
-1,524
-75% -$55K ﹤0.01% 3893
2020
Q2 		$77K Buy
+2,040
New +$67.2K ﹤0.01% 2684
2020
Q1 		– Sell
-485
Closed -$25K – 3003
2019
Q4 		$25K Buy
485
+283
+140% +$16.4K ﹤0.01% 1776
2019
Q3 		$11K Buy
+202
New +$10.4K ﹤0.01% 2853
2019
Q1 		– Sell
-204
Closed -$7K – 3751
2018
Q4 		$7K Buy
+204
New +$7.36K ﹤0.01% 2665
2018
Q3 		– Sell
-3,626
Closed -$116K – 3729
2018
Q2 		$116K Buy
+3,626
New +$149K 0.01% 1349
2018
Q1 		– Sell
-220
Closed -$12K – 3214
2017
Q4 		$12K Sell
220
-1,945
-90% -$108K ﹤0.01% 2421
2017
Q3 		$126K Buy
+2,165
New +$113K 0.01% 1143
2016
Q3 		– Sell
-675
Closed -$36K – 3585
2016
Q2 		$36K Buy
675
+575
+575% +$27.1K ﹤0.01% 1784
2016
Q1 		$4K Sell
100
-510
-84% -$20.7K ﹤0.01% 2846
2015
Q4 		$23K Buy
+610
New +$23.3K ﹤0.01% 1142
2015
Q3 		– Sell
-1,026
Closed -$34K – 3956
2015
Q2 		$34K Buy
1,026
+572
+126% +$20.4K ﹤0.01% 1650
2015
Q1 		$19K Buy
454
+131
+41% +$5.3K ﹤0.01% 2280
2014
Q4 		$13K Buy
323
+265
+457% +$10.4K ﹤0.01% 1893
2014
Q3 		$2K Sell
58
-219
-79% -$9.46K ﹤0.01% 3764
2014
Q2 		$13K Sell
277
-524
-65% -$23.3K ﹤0.01% 2134
2014
Q1 		$33K Buy
801
+35
+5% +$1.3K ﹤0.01% 1397
2013
Q4 		$29K Sell
766
-1,836
-71% -$56.6K ﹤0.01% 1917
2013
Q3 		$63K Buy
2,602
+2,428
+1,395% +$54.5K 0.01% 1701
2013
Q2 		$3K Buy
+174
New +$2.51K ﹤0.01% 3251

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tower Research Capital (TRC)'s ANIK Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Anika Therapeutics (ANIK) stake by 45% in Q1 2026, selling an estimated $8.32K and leaving 880 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3774.

Tower Research Capital (TRC) first reported a position in ANIK in Q2 2013 and has held it in 42 quarters since. The position peaked at $212K in Q2 2024. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Tower Research Capital (TRC) held 880 shares of Anika Therapeutics worth $12.8K as of Q1 2026.
  • Tower Research Capital (TRC) sold 717 Anika Therapeutics shares in Q1 2026, an estimated $8.32K.
  • Anika Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3774 holding.
  • Tower Research Capital (TRC) first reported a position in Anika Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s Anika Therapeutics position peaked at $212K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.